# SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

> **NCT05902962** · PHASE1 · COMPLETED · sponsor: **PYC Therapeutics** · enrollment: 17 (actual)

## Conditions studied

- Retinal Dystrophy
- PRPF31 Mutationassociated Retinal Dystrophy
- RP11

## Interventions

- **DRUG:** VP-001

## Key facts

- **NCT ID:** NCT05902962
- **Lead sponsor:** PYC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-20
- **Primary completion:** 2025-10-08
- **Final completion:** 2025-10-08
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05902962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05902962, "SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05902962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*